A Novel Homozygous MC2R Variant Leading to Type-1 Familial Glucocorticoid Deficiency

Idris Mohammed1,2, Basma Haris1, Khalid Hussain1,*

1Division of Endocrinology, Department of Pediatrics, Sidra Medicine, Doha, Qatar; and
2College of Health & Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar

Correspondence: Professor Khalid Hussain MBChB MD MRCP MRCPC MSc, Professor of Pediatrics, Weill Cornell Medicine-Qatar, Division Chief – Endocrinology, Department of Pediatric Medicine, Sidra Medicine, PO Box 26999; Education City North Campus, Doha, Qatar, Email: khussain@sidra.org

Abstract

Context: Type 1 familial glucocorticoid deficiency (FGD) (OMIM #607397) is a rare autosomal recessive disorder due to mutations in melanocortin-2-receptor (MC2R) gene encoding the G protein-coupled adrenocorticotropic (ACTH) transmembrane receptor.

Objective: The aim of the study is to describe 2 siblings born to a healthy consanguineous family presenting with clinical and biochemical features of FGD, harboring a novel homozygous MC2R variant.

Methods: Both patients are siblings born at term via normal delivery with normal birth weights. The first sibling presented with symptoms of hypoglycemia, repeated episodes of infections starting from 2 days of age. At 18 months of age, low serum cortisol was found, and he was started on hydrocortisone replacement therapy. The second sibling developed hypoglycemia on day 1 after birth, investigations revealed low serum sodium and cortisol levels and was also commenced on hydrocortisone treatment. Whole exome sequencing (WES) and in vitro functional studies on cell line transfected with wild-type and mutant plasmid clones were undertaken.

Results: VES revealed a novel homozygous missense mutation c.326T>A, p.Leu109Gln in the MC2R gene. In-silico prediction tools predicted the effect of this mutation to be deleterious. In vitro study using HEK293 cells transfected with MC2R wild-type and mutant clones showed a defect in protein expression and cAMP generation when stimulated with ACTH.

Conclusion: Homozygous semiconserved p.Leu109Gln mutation disrupts cAMP production and MC2R protein expression leading to ACTH resistance. This study provides additional evidence that this novel pathogenic variant in MC2R results in FGD phenotypes.

Key Words: MC2R, ACTH, adrenal insufficiency, familial glucocorticoid deficiency, next-generation sequencing

Abbreviations: ACTH, adrenocorticotropic hormone; cAMP, cyclic adenosine monophosphate; DMEM, Dulbecco's Modified Eagle Medium; FGD, familial glucocorticoid deficiency; GPCR, G protein coupled receptor; MC2R, melanocortin-2 receptor; MRAP, melanocortin-2 receptor accessory protein; PCR, polymerase chain reaction; TSH, thyrotropin (thyroid-stimulating hormone); WES, whole exome sequencing.
ACTH, consequently manifesting features of FGD [14]. There is only 1 MC2R activating mutation (F278C) reported in literature which is associated with Cushing syndrome [15]. Here we report a novel homozygous loss-of-function MC2R mutation in 2 siblings with hypoglycemia, recurrent infections, and low serum cortisol level.

**Case Description**

**Patient 1**
Sibling 1 is a 4-year-old boy who was born at term via normal delivery with a birth weight of 3.45 kg. The parents are first-degree cousins. The mother was well during the pregnancy. The patient was admitted to the neonatal unit at a hospital outside Qatar and was evaluated but no cause was found as per the parents. He developed repeated episodes of neonatal sepsis starting at the age of 2 days with recurrent episodes of hypoglycemia and infections. At 18 months of age, the patient became unwell and was admitted in our center with hypoglycemia. Investigations confirmed a high plasma ACTH and low cortisol level. Interestingly the serum thyroxine level was also low and the thyrotropin (thyroid-stimulating hormone; TSH) was found to be high. The patient was therefore started on hydrocortisone replacement therapy (12 mg/m²/day) and thyroxine supplementation (25 mcg daily). The serum insulin and C-peptide levels were undetectable. There was no failure to thrive or any dysmorphic features, but the patient had increased pigmentation which improved after starting replacement therapy with hydrocortisone.

**Patient 2**
Sibling 2 is the second child of the same family. She was born at 38 weeks of gestation via normal vaginal delivery with a birth weight of 3.54 kg. The mother had gestational diabetes in this pregnancy that was managed with dietary control only. The patient developed hypoglycemia (2.1 mmol/L) on day 1 after birth. She was monitored closely, and investigations revealed low serum cortisol levels as well as high plasma ACTH levels. A short Synacthen test showed no response to cortisol, so the baby was started on hydrocortisone treatment (12 mg/m²/day). Her serum TSH and plasma aldosterone levels were elevated.

Table 1 summarizes the biochemical investigations in both siblings.

**Table 1.** Clinical investigations of the 2 patients

| Test                          | Value   | Reference |
|------------------------------|---------|-----------|
| Age at time of test          | Sibling 1 18 months 4 days 5-60 pg/mL |
| Plasma ACTH                  | >1500   | 952 69-632 nmol/L |
| Serum cortisol               | <22     | <22 69-632 nmol/L |
| Plasma aldosterone           | 151     | 2800 194-2579 pmol/L |
| Serum sodium                 | 137     | 136 135-145 mmol/L |
| Serum potassium              | 3.7     | 5.2 3.5-5.2 mmol/L |
| Serum bicarbonate            | 23      | 21 21-28 mmol/L |
| Serum chloride               | 104     | 99 95-110 mmol/L |
| Serum TSH                    | 9.23    | 10.7 0-4.4 mlU/L |
| Serum free T4                | 9.1     | 17.6 9.5-17.8 pmol/L |
| Plasma renin activity (PRA)  | 3.7     | Not done 1.5-3.5 ng/mL/hr |

**Methodology**

**Whole Exome Sequencing**

After obtaining written consent from the family, blood was collected from the patients and their parents for whole exome sequencing (WES). Genomic DNA was extracted from peripheral blood using the QiAamp DNA blood midi kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Genomic DNA quality was assessed using Nanodrop (Life technologies, Darmstadt, Germany). The genomic DNA samples were sequenced at Sidra Medicine using an HiSeq 2000 sequencer (Illumina, San Diego, CA, USA). High quality reads were aligned to the human genome reference GRCh37 assembly (hg19). VariantRecalibrator and GATK Haplotypecaller tools were used for variant calling. Sanger sequencing was used to confirm variant by region-specific primers (forward: 5’TCCAGGCACCCATGTACTTT 3’, reverse: 5’AGATGGTGATGTAGCGGTCC 3’), which covered the region of interest. Primers were designed using primer3 software (http://primer3.ut.ee/). After confirming the variant identified in WES on first sibling using Sanger sequencing, we targeted sequencing on the second sibling. The second sibling was homozygous for this variant.

**Cell Culture and MC2R and MRAP Vector Expression in HEK293 Cells**

The full-length human MC2R wild-type (WT) (NM_001291911.1) and MC2R mutant cDNA cloned in pCDNA3.1-C-(k)DYK vector were purchased from GenScript. Human MRAP clone cDNA clone expression plasmid cloned in pCMV3-MRAP-OFPSpark was purchased from (Sino Biological). HEK293A cells were maintained in a complete Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin mix in 5% CO2 at 37 °C in a humidified incubator. Cells were seeded in a 6-well plate; 24 hours after seeding, cells were transfected using FuGENE HD (Promega) at approximately 80% confluence with total DNA of 3 μg of DNA per well (duplicate) with both wild-type and mutant vectors. Then 48 hours after transfection, the transfected cells were placed into complete DMEM media.
containing 400 μg/mL of geneticin selective antibiotics (G418 sulfate) (Thermo Fisher Scientific) to select for G418-resistant cells. After 4 weeks, the cells were harvested to assay the expression of the clones to enable us to estimate the relative amount of expression in transfected cells in comparison to the endogenous (untransfected HEK293 cells) expression using real-time polymerase chain reaction (PCR).

Real-Time PCR of MC2R Plasmid Clones

Total RNA was isolated from transfected (wild-type and mutant) and untransfected (endogenous control) HEK293 cells using RNeasy mini kit (Qiagen). The RNA concentration was quantified using Nanodrop. First-strand cDNA was synthesized from 1 μg RNA retrotranscribed using SuperScript III First Strand Synthesis System (Thermo Fisher Scientific). Gene-specific primers (rtMC2R-forward: 5′TCCAGGCCACCCATGTACTTT3′; rtMC2R-reverse: 5′GTCATCGGCTGTGGTTTCA3′ [166 bp] and rtGAPDH-forward: 5′CAGCCTCAAGATCATCAGCA3′, rtGAPDH-reverse: 5′GGTCATGAGTCCTTCCACGA3′ [103 bp]) were used for PCR amplification. The amplification reactions were carried out in QuantStudio 12K flex real-time PCR system (Applied Biosystems, ABI). Samples were measured in triplicates and mRNA levels were normalized against GAPDH using ΔΔCT method [16]. The data presented are means ± SE with *P < 0.05 and **P < 0.01.

ACTH Stimulation and cAMP Assay

Stably transfected HEK293 cells with the wild-type MC2R-WT and MC2R-mutant were seeded in a 6-well plate and grown until they reached approximately 80% confluent. After 80% confluency both wild-type and mutant cells were transiently co-transfected with 3 μg of MRAP DNA per well. Cells were assayed for cAMP assay experiment after 48 hours of co-transfection with MRAP. Cells were incubated with Opti-MEM reduced-serum medium (Gibco) for 2 hours, in the presence of 3-isobutyl-1-methylxanthine (IBMX) at a concentration of 1 mmol/L. After a starvation period of 2 hours, the cells were stimulated with ACTH-(1–24) (Sigma-Aldrich) with different concentrations per well (10⁻¹² to 10⁻⁵ mol/L) for 3 hours. After the incubation, cells and media were harvested, heated, and were used for cAMP assay according to a previously established method [17]. The cAMP ELISA assay was performed using cAMP Direct Immunoassay Kit (BioVision, Cat# K371, RRID:AB_2909598). Acetylated protocol was applied for the assay following the manufacturer’s guidelines. All the expression results were normalized to protein concentration using BCA protein assay kit (Thermo Fisher Scientific).

Statistical Analysis

For protein expression and cAMP production measurement assays, results are presented for duplicates as mean ± SD using cells from 2 independent experiments. One-way ANOVA was performed using GraphPad Prism version 8.02 (GraphPad Software, San Diego, California).

Results

Whole exome sequencing of the 2 patients revealed a novel homozygous missense mutation, a substitution of thymine by adenine (c.326T>A), located within exon 2 of the MC2R gene, whereas the parents were carriers for this mutation. This single base pair resulted in a substitution of leucine (nonpolar, strong hydrophobic side chain) by glutamine (polar, strong hydrophilic side chain) at position 109 (p.Leu109Gln). This mutation overlaps with the 2 transcripts of MC2R and resides in the third transmembrane domain of the gene. We confirmed the homozygous T to A transversion mutation detected by WES using Sanger sequencing. The parents were heterozygous carriers for this mutation (Fig. 1). Variant effect prediction tools: SIFT (https://sift.bii.a-star.edu.sg/), Polyphen2 (http://genetics.bwh.harvard.edu/pph2/), and MutationTaster (http://www.mutationtaster.org) predicted this mutation to be deleterious, probably damaging, and

Figure 1. Pedigree diagram showing consanguineous parents with 2 affected children. Sanger sequencing demonstrating the c.326T>A homozygous mutation in both patients (lower panel) and heterozygous genotype in both parents (upper panel). Black arrow indicates the nucleotide position C.326.
Mutant MC2R Cells Generate Decreased cAMP When Stimulated With ACTH

We noticed reduced protein expression of the mutant p.Leu109Gln compared with the wild-type expressing cells. We further assessed the expression using real-time PCR, and the mutant cells showed decreased mRNA expression (Fig. 2). After confirming reduced mRNA and protein in the mutant cells we assessed the cAMP levels in wild-type, mutant (co-transfected with MC2R and MRAP clones), and untransfected HEK293 cells as a negative control. Mutant cells resulted in generation of very low cAMP in comparison with wild-type cells (Fig. 3).

Discussion

In this study, we report the clinical findings and in vitro functional analysis of a novel MC2R mutation in 2 siblings, born to a healthy consanguineous family. The 2 patients presented with the typical phenotype of FGD-1 with hypoglycemia, recurrent infections, high plasma ACTH, and low serum cortisol level. We identified a homozygous novel mutation, c.326T>A, p.Leu109Glu in the MC2R gene using WES. Leucine 109 is located in the third transmembrane domain of the 7 transmembrane domains of the GPCR. This third transmembrane domain is important and plays a critical role in ligand selectivity and potency for receptor activation [18]. Another unique feature of this domain is that it is the least exposed to lipid membrane, buried inside compared with the GPCR domains [19]. Previously reported mutations in Human Gene Mutation Database (HGMD) in the third transmembrane domain of MC2R gene showed decreased cAMP production. Variants p.As103Asn, p.As107Asn, and p.Arg128Cys impair ACTH receptor function and result in significant impairment of cAMP generation; a Thy129Cys mutant caused significant intracellular retention, and p.Ile130Asn exhibited partial trafficking impairment [20]. Tsigos and colleagues showed that the p.Ser120Arg variant leads to ACTH resistance [21]. The variant p.Ala126Ser alters MC2R structure and function [22].

To examine the effect of the novel mutation (p.Leu109Gln), we undertook in vitro functional analysis by transfecting wild-type and mutant MC2R clones in HEK293 cells. We stimulated HEK293 cells with ACTH(1-24) with different concentrations, ranging from ACTH 12 mol/L to 6 mol/L to measure cAMP generation. The analysis of duplicate run samples showed very low cAMP generation when stimulated with ACTH compared to wild-type cell lines, indicating impaired function of the mutant ACTH receptor. This result confirms that the p.Leu109Gln mutation affects signaling pathways due to a defect in generating a secondary messenger cAMP, consequently leading to ACTH resistance. However, under normal physiology, downstream signaling of cAMP plays a crucial role in activation of targets such as protein kinase A and cAMP response element-binding protein (CREB), which regulate transcription of genes involved in steroidogenic enzymes synthesis and secretion [13].

Since the mode of inheritance of the MC2R gene is autosomal recessive, the frequency should be higher in societies such as among the Arabs which have a long tradition of consanguinity [23]. However, to our knowledge, there are only 3 studies of MC2R gene mutations in the literature from the Arab countries. The first study was by Chan and colleagues [24], which reported a patient of Saudi Arabian origin carrying double homozygous MC2R mutations (Y129C and F278C) who was diagnosed with FGD and presented with spastic quadriplegia due to hypoglycemic episodes. The second study identified MC2R mutations in 3 patients of Arab origin: Kuwaiti, Lebanese, and Sudanese backgrounds. The patients from Kuwaiti and Sudanese origin carried frameshift mutations, c. 459_460insC (p.I154fsX248), and c.539C>(p.S180X) respectively. The Lebanese origin patient carried a nonsense mutation c.539C>(p.S180X) [25]. In the third study, Kandari et al reported a homozygous point mutation in the MC2R gene in 5 Arab kindreds from Saudi Arabia and Kuwait. All the 5 patients carried a common mutation c.459_460insC resulting in a frameshift at amino acid position 248 (p.I154fsX248) [26]. The lack of reported cases in the literature in this consanguineous population could be due to misdiagnosis of FGD.

Since we identified the genetic abnormality in the first sibling using WES, it was easy to make the diagnosis very early on the second sibling and to start treatment early. With delayed
diagnosis, inadequate treatment, or if left untreated, FGD leads to fatal complications or severe mental disabilities [27].

We observed elevated serum TSH levels in patient 2 on day 4 of birth; however, since the patient's serum T4 level was normal, medication was not started. On repeat testing at 2 months of age, the patient had normal serum TSH and T4 levels. The plasma aldosterone level showed an elevated levels only in patient 2 during her neonatal period, and the normal reference range for plasma aldosterone is very wide as well. Therefore, we do not think this finding is associated with the MC2R mutation in our patient. Serum insulin as well C-peptide in patient 1 was undetectable. This is in keeping with our finding, since MC2R mutations are not associated with hyperinsulinemia hypoglycemia.

Our first patient has hypothyroidism and as far as we know there are only few cases of MC2R mutations and hypothyroidism. All the 5 patients reported by Al Kandari et al with homozygous MC2R mutation c.459_560insC presented with thyroid dysfunction ranging from neonatal thyroid dysfunction to subclinical hypothyroidism [26]. Another study reported a Caucasian girl with a mutation in MC2R p.S74I, diagnosed with primary hypothyroidism [27]. Recently, Heshmatzad et al reported a 2-year-old boy with MC2R mutation, who presented with hypothyroidism and congenital adrenal hypoplasia [28]. The link between MC2R and hypothyroidism is not known yet; future investigation is needed to elucidate the underlying mechanism responsible for hypothyroidism.

Funding
This research was supported by the Qatar National Research Fund [QNRF-N NPRP 10-6100017-AXX] awarded to Professor Khalid Hussain.

Ethics Statement
This study was approved by the Institutional Review Board (IRB) for the protection of human subjects in Sidra Medicine, Qatar (IRB reference number 1702007592). Informed consent was obtained from the parents as required. A copy of the written consent from the parents is available for review by the editor of this journal.

Disclosures
All authors have no conflicts of interest to disclose.

Author Contributions
I.M. and B.H. collected patient information, recruited the patients, analyzed and interpreted the data, and drafted the manuscript. K.H. designed the study, obtained funding, and reviewed and edited the manuscript. I.M. analyzed genetic data and performed the laboratory confirmatory experiments.

Data Availability
Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

References
1. Clark AJL, Weber A. Adrenocorticotropic insensitivity syndromes. Endocr Rev. 1998;19(6):828-843.
2. Shepard TH, Landing BH, Mason DG. Familial Addison’s disease; case reports of two sisters with corticoid deficiency unassociated with hypoaldosteronism. AMA J Dis Child. 1959;97(2):154-162.
3. Fridmanis D, Roga A, Klovins J. ACTH Receptor (MC2R) specificity: what do we know about underlying molecular mechanisms? Front Endocrinol (Lausanne). 2017;8:13. doi:10.3389/fendo.2017.00013
4. Chung T-TLL, Chan LF, MethereLLA, Clark AJL. Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2. Clin Endocrinol (Oxf). 2010;72(5):589-594.
5. Hughes CR, Guasti L, Meimariadu ET, et al. MC2R mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest. 2012;123(3):814-820. doi:10.1172/JCI62224
6. Meimariadu E, Kowalczyk J, Guasti L, et al. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet. 2012;44(7):740-742. doi:10.1038/ng.2299
7. Lakshmi V, Rajesh J, Das Dhananj K, Sudha R, Daksha S, Shiny B. Identification of novel mutations in STAR gene in patients with lipoid congenital adrenal hyperplasia: a first report from India. J Clin Res Pediatr Endocrinol. 2013;5(2):121-124.
8. Prasad R, Chan LF, Hughes CR, et al. Thioredoxin reductase 2 (TXNRD2) mutation associated with familial glucocorticoid deficiency (FGD). J Clin Endocrinol Metab. 2014;99(8):E1556-E1563. doi:10.1210/jc.2013-3844
9. Lovric S, Goncalves S, Gee HY, et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 2017;127(3):912-928. doi:10.1172/JCI89626
10. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. doi:10.1210/er.2006-0034
11. Jackson DS, Ramachandrapa S, Clark AJ, Chan LF. Melanocortin receptor accessory proteins in adrenal disease and obesity. Front Neurosci. 2015;9:213. doi:10.3389/fnins.2015.00213
12. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Sci. 1992;257(5074):1248-1251.
13. Gallo-Payer N, Payer MD. Mechanism of action of ACTH: beyond cAMP. Microsc Res Tech. 2003;61(3):275-287. doi:10.1002/jemt.10337
14. Novoselova TV, Chan LF, Clark AJL. Pathophysiology of melanocortin receptors and their accessory proteins. Best Pract Res Clin Endocrinol Metab. 2018;32(2):93-106. doi:10.1016/j.beem.2018.02.002
15. Swords FM, Baig A, Malchoff DM, et al. Impaired desensitization of a mutant adrenocorticotropic receptor associated with apparent constitutive activity. Mol Endocrinol. 2002;16(12):2746-2753.
16. Livak KJ, Schmittingen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;23(4):402-408.
17. Fluck CE, Martens JW, Conte FA, Miller WL. Clinical, genetic, and functional characterization of adrenocorticotropin receptor mutations using a novel receptor assay. J Clin Endocrinol Metab. 2002;87(9):4318-4323.
18. Yang Y, Mishra V, Crasto CJ, Chen M, Dimmitt R, Harmon CM. Third transmembrane domain of the adrenocorticotropic receptor is critical for ligand selectivity and potency. J Biol Chem. 2015;290(12):7685-7692. doi:10.1074/jbc.M114.596122
19. Baldwin JM. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 1993;12(4):1693-1703.
20. Chung TT, Webb TR, Chan LF, et al. The majority of adrenocorticotropic (melanocortin 2 receptor) mutations found in familial glucocorticoid deficiency type 1 lead to defective trafficking of the receptor to the cell surface. J Clin Endocrinol Metab. 2008;93(12):4948-4954. doi:10.1210/jc.2008-1744
21. Tsigos C, Arai K, Hung W, Chrousos GP. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropic receptor gene. *J Clin Invest.* 1993;92(5):2458-2461. doi:10.1172/JCI116853

22. Artigas RA, Gonzalez A, Riquelme E, et al. A novel adrenocorticotropic receptor mutation alters its structure and function, causing familial glucocorticoid deficiency. *J Clin Endocrinol Metab.* 2008;93(8):3097-3105.

23. Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. *Reprod Health.* 2009;6(1):17. doi:10.1186/1742-4755-6-17

24. Chan LF, Chung T-T, Massoud AF, Metherell LA, Clark AJL. Functional consequence of a novel Y129C mutation in a patient with two contradictory melanocortin-2-receptor mutations. *Eur J Endocrinol.* 2009;160(4):705-710. doi:10.1530/EJE-08-0636

25. Chan LF, Metherell LA, Krude H, et al. Homozygous nonsense and frameshift mutations of the ACTH receptor in children with familial glucocorticoid deficiency (FGD) are not associated with long-term mineralocorticoid deficiency. *Clin Endocrinol (Oxf).* 2009;71(2):171-175.

26. Al Kandari HM, Katsumata N, Al Alwan I, Al Balwi M, Rasoul MSA. Familial glucocorticoid deficiency in five Arab kindreds with homozygous point mutations of the ACTH receptor (MC2R): genotype and phenotype correlations. *Horm Res Paediatr.* 2011;76(3):165-171. doi:10.1159/000328035

27. Al Jneibi F, Hen T, Rajah J, Nair R. Early diagnosis in familial glucocorticoid deficiency. *Dermatoendocrinol.* 2017;9(1):e1310787. doi:10.1080/19381980.2017.1310787

28. Mathew RP, Kovacs WJ. Short stature in a patient with familial glucocorticoid deficiency. *J Pediatr Endocrinol Metab.* 2011;24(7–8):569-571.

29. Heshmatzad K, Mahdieh N, Rabbani A, Didban A, Rabbani B. The genetic perspective of familial glucocorticoid deficiency: *in silico* analysis of two novel variants. *Int J Endocrinol.* 2020;2020:1-8.